Tag

Your search for Short-term regimen returned 5 results.


Real-world impact of sofosbuvir HCV regimens

New study addresses the real-world effectiveness of sofosbuvir (SOF)-based anti-HCV regimens in a diverse patient population consisting of difficult to treat patients. More than a quarter of the assessed US Veterans Affairs (VA) population with chronic HCV infection were African American, almost 90% were over the age of 55, over a third were overweight, and substan...

Read More


Hepatitis C RAVs are Not a Barrier to Retreatment

Study published in the journal Hepatology suggests that sofosbuvir plus peginterferon and ribavirin for 12 weeks is effective and safe in patients who have not achieved SVR with prior regimens of one or more direct-acting antiviral (DAA) agents plus peginterferon and ribavirin. High rates of SVR12 are achieved regardless of the presence of resistance associated ...

Read More


Dr. E Lebovics: Post-EASL 2015 HCV Interview

During our last interview, you mentioned that extending the use of all oral, interferon-free, hepatitis C regimens to special populations including those with decompensated cirrhosis, post-transplant, and renal failure is an area of great interest. We would like to hear your thoughts on relevant clinical data presented at The International Liver Congress™ 2015, ...

Read More


6-week Hepatitis C DAA drug regimen is effective

A simple 6-week course of three direct-acting antiviral drugs appears to be effective and well tolerated in patients with chronic HCV genotype 1 infection without cirrhosis Simple hepatitis C treatment regimens with a short duration, low pill burdens, and few adverse effects could improve patient adherence, which is vital considering that the ultimate goal is to ...

Read More


Short-duration, IFN- RBV-free regimen for HCV 3

A short-duration, interferon- and ribavirin-free regimen of daclatasvir plus sofosbuvir is efficacious and tolerable in patients with chronic hepatitis C genotype 3 infection Patients with chronic hepatitis C genotype 3 (HCV 3) infection have a higher risk of progression to cirrhosis, as well as development of steatosis or hepatocellular carcinoma, than those ...

Read More